Development of a Decision-making Aid for Referring Severe Kidney Injury Patients for Nephrology Consultations (IRA Cible)

Acute kidney injury is a frequent and growing complication associated with a risk of progressing into a chronic kidney disease. Recent guidelines have recommended systematic consultations with a nephrologist 3-6 months following hospitalization. Risk factors of developing chronic kidney disease between hospital visits are understudied.

Study Overview

• Status: Completed
• Conditions: Chronic Kidney Diseases; Acute Kidney Injury
• Intervention / Treatment: Other: monitoring for progression to chronic kidney disease

• Study Type: Observational
• Enrollment (Actual): 319

Contacts and Locations

Study Locations

• France
  • Nîmes, France, 30029
    • CHU Nimes

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Patients undergoing dialysis for acute kidney injury. All new adults (>18 years old) hospitalized in a university center with severe AKI was included from August 2016 to December 2017. Inclusion criteria was a severe AKI defined by dialysis start for AKI or an increase of Scr upper 354 μmol/L. Exclusion criteria was CKD stage 5 , patients living with kidney transplant, plan dialysis for bilateral surgery nephrectomy, patient witch justice protection and refuse to participate. Eligible patients were identified by physicians for ICU and nephrology department and by laboratory biochemistry department for others wards. A Biochemistry alert system controlled the exhaustively of inclusion in ICU and Nephrology department during the period of the study.

Description

Inclusion Criteria:

• Age >18 years
• Suffering from acute kidney injury treated with dialysis
• hospitalized in a university center from August 2016 to December 2017 with severe AKI defined according to 2 of the 3 criterion definitions of KDIGO stage AKI: an increase in SCr above 354 μmol/Lor renal replacement therapy (RRT) indication, but not the 3-fold increase in SCr increase within 7 days with SCr below 354 μmol/L.
• The patient has been informed and does not oppose the study
• The patient is insured or the beneficiary of a health insurance policy

Exclusion Criteria:

• The patients is under judicial protection or state guardianship
• Patient has chronic kidney disease(CKD) KDIGO stage 5
• It proves impossible to give the patient clear information
• patients living with kidney transplant
• plan dialysis for bilateral surgery nephrectomy
• patient refuse to participate and patients with no health insurance

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Patients with acute kidney injury; Requiring treatment with dialysis	Other: monitoring for progression to chronic kidney disease; Collect clinical information and assess risk factors

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Develop a prognostic score of progression to chronic kidney disease at 6 months in patients requiring hospitalization for dialysis for acute kidney injury to identify those who would benefit from consultation with a nephrologist	6 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Identify new risk factors for progression to chronic kidney disease at 6 months post dialysis for acute kidney injury pre-hospitalization and during hospitalization and day of discharge		6 months
Identify renal phenotype of patients with chronic kidney disease	characterization from renal biopsy	6 months
Evaluate mortality during hospital stay		1 months
Evaluate mortality at medium-term		6 months
Identify specific therapeutic interventions put into place during the 6 month consultation		6 months

Collaborators and Investigators

• Sponsor: Centre Hospitalier Universitaire de Nīmes

Publications and helpful links

General Publications

• Cardinale A, Messikh Z, Antoine V, Aglae C, Reboul P, Cariou S, Muller L, Lefrant JY, Moranne O. Specificity of severe AKI aetiology and care in the elderly. The IRACIBLE prospective cohort study. J Nephrol. 2022 Nov;35(8):2097-2108. doi: 10.1007/s40620-022-01322-z. Epub 2022 May 3.

Study record dates

Study Major Dates

• Study Start (Actual): August 20, 2016
• Primary Completion (Actual): December 31, 2017
• Study Completion (Actual): June 15, 2018

Study Registration Dates

• First Submitted: June 16, 2017
• First Submitted That Met QC Criteria: June 16, 2017
• First Posted (Actual): June 20, 2017

Study Record Updates

• Last Update Posted (Estimated): November 17, 2025
• Last Update Submitted That Met QC Criteria: November 14, 2025
• Last Verified: November 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Urogenital Diseases; Pathologic Processes; Male Urogenital Diseases; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Chronic Disease; Disease Attributes; Renal Insufficiency; Pathological Conditions, Signs and Symptoms; Acute Kidney Injury; Renal Insufficiency, Chronic
• Other Study ID Numbers: LOCAL/2016/OM-01

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No